Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Bosulif
Bosutinib is a tyrosine kinase inhibitor (TKI) primarily used to treat chronic myeloid leukemia (CML). It works by blocking specific proteins that promote the growth of cancer cells, namely BCR-ABL and SRC family kinases. Bosutinib is typically prescribed for adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) CML who have previously received other TKI therapies.
Treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in adult patients with resistance or intolerance to prior therapy.
Hepatotoxicity, including liver failure, has been reported. Severe diarrhea, including cases requiring hospitalization, has been reported. QTc interval prolongation has been observed.
Outcome:
Increased bosutinib levels
Mechanism:
Inhibition of CYP3A4 metabolism
Outcome:
Potential for altered INR
Mechanism:
CYP2C9 interaction
Outcome:
No clinically significant interaction expected
Mechanism:
None
Most likely new formulation: Extended-release formulation (2026, 60% confidence)
Based on current usage trends and clinical trial results, there is a 70% likelihood of bosutinib maintaining its current indication for CML treatment over the next 5 years.
Tyrosine Kinase Inhibitor, Antineoplastic Agent
Pyrimidine derivative